Flexible, agile and proactive laboratory services dedicated to global clinical development
For over 25 years, the bioanalytical services group at ICON has provided analytical testing services to meet the research and development challenges of the pharmaceutical and biotechnology industry.
ICON Central Laboratories is dedicated exclusively to central laboratory testing and the associated services for clinical trials.
We bring operational experience, scientific and technical expertise, and a range of innovative tools and ancillary services for sponsors and sites to deliver quality results. Central, bioanalytical, and specialty labs are located in key global regions including the US, Singapore, China and Ireland. All ICON laboratories are CAP accredited, GCP or GLP certified.
Digital Pathology at ICON Laboratories reflects a holistic approach to innovating anatomic pathology for the modern needs of global clinical trials. It is built on globally harmonised, state-of-the-art histopathology practices and ICON’s proprietary host platform for image data called MIRA (Medical Image Review and Analysis). Integrated with ICON’s global LIMS, the beginning-to-end offering is a seamless Digital Pathology solution created to optimise global central pathology review in support of today’s elaborate clinical trial designs.
The move to Beijing represents the successful conclusion of a complex relocation project, which included operation from a temporary facility in Shanghai while the former lab location in Tianjin was decommissioned. During all this time, service to clients was maintained without interruption. While ICON Labs has had a presence in China since 2007, this is the first time that the lab will be co-located with other ICON services in Beijing.
The new 950 sqm facility will support global drug development and will also house ICON clinical research and other staff. Current testing services include hematology, chemistry, urinalysis, coagulation, immunology, HbA1c and DNA extraction. A range of specialty lab testing capabilities such as histopathology, PCR, slide imaging and ELISA will be installed by the end of 2021. BioA lab capacity is also planned for the future.